Similar articles for PMID: 29864378

Year	Number of Results
2004	1
2006	1
2007	1
2009	1
2010	2
2011	1
2012	2
2013	4
2014	10
2015	11
2016	9
2017	9
2018	27
2019	16
2020	4
2022	3
2024	0

1

ARCHER 1050: Hitting an Important Mark in EGFR-Mutant Lung Cancer?

Piotrowska Z, Gainor JF. Piotrowska Z, et al. J Clin Oncol. 2018 Aug 1;36(22):2241-2243. doi: 10.1200/JCO.2018.79.3059. Epub 2018 Jun 4. J Clin Oncol. 2018. PMID: 29864378 No abstract available.

2

Dacomitinib: another option for EGFR-mutant lung cancer?

Mitsudomi T. Mitsudomi T. Lancet Oncol. 2014 Dec;15(13):1408-1409. doi: 10.1016/S1470-2045(14)70487-5. Epub 2014 Nov 5. Lancet Oncol. 2014. PMID: 25456351 No abstract available.

3

Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.

Wu YL, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, Tsuji F, Linke R, Rosell R, Corral J, Migliorino MR, Pluzanski A, Sbar EI, Wang T, White JL, Nadanaciva S, Sandin R, Mok TS. Wu YL, et al. Lancet Oncol. 2017 Nov;18(11):1454-1466. doi: 10.1016/S1470-2045(17)30608-3. Epub 2017 Sep 25. Lancet Oncol. 2017. PMID: 28958502 Clinical Trial.

4

Dacomitinib in the Management of Advanced Non-Small-Cell Lung Cancer.

Lau SCM, Batra U, Mok TSK, Loong HH. Lau SCM, et al. Drugs. 2019 Jun;79(8):823-831. doi: 10.1007/s40265-019-01115-y. Drugs. 2019. PMID: 31069718 Review.

5

Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial.

Jänne PA, Ou SI, Kim DW, Oxnard GR, Martins R, Kris MG, Dunphy F, Nishio M, O'Connell J, Paweletz C, Taylor I, Zhang H, Goldberg Z, Mok T. Jänne PA, et al. Lancet Oncol. 2014 Dec;15(13):1433-1441. doi: 10.1016/S1470-2045(14)70461-9. Epub 2014 Nov 5. Lancet Oncol. 2014. PMID: 25456362 Clinical Trial.

6

Dacomitinib, a second-generation irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) to treat non-small cell lung cancer.

Nagano T, Tachihara M, Nishimura Y. Nagano T, et al. Drugs Today (Barc). 2019 Apr;55(4):231-236. doi: 10.1358/dot.2019.55.4.2965337. Drugs Today (Barc). 2019. PMID: 31050691 Review.

7

Prediction of sensitivity to gefitinib/erlotinib for EGFR mutations in NSCLC based on structural interaction fingerprints and multilinear principal component analysis.

Zou B, Lee VHF, Yan H. Zou B, et al. BMC Bioinformatics. 2018 Mar 7;19(1):88. doi: 10.1186/s12859-018-2093-6. BMC Bioinformatics. 2018. PMID: 29514601 Free PMC article.

8

Gefitinib Versus Adjuvant Chemotherapy in Patients With Stage II-IIIA Non-Small-Cell Lung Cancer Harboring Positive EGFR Mutations: A Single-Center Retrospective Study.

Xie H, Wang H, Xu L, Li M, Peng Y, Cai X, Feng Z, Ren W, Peng Z. Xie H, et al. Clin Lung Cancer. 2018 Nov;19(6):484-492. doi: 10.1016/j.cllc.2018.05.007. Epub 2018 May 26. Clin Lung Cancer. 2018. PMID: 30369426

9

EGFR mutation status of paired cerebrospinal fluid and plasma samples in EGFR mutant non-small cell lung cancer with leptomeningeal metastases.

Zhao J, Ye X, Xu Y, Chen M, Zhong W, Sun Y, Yang Z, Zhu G, Gu Y, Wang M. Zhao J, et al. Cancer Chemother Pharmacol. 2016 Dec;78(6):1305-1310. doi: 10.1007/s00280-016-3155-y. Epub 2016 Oct 21. Cancer Chemother Pharmacol. 2016. PMID: 27770237

10

Functional cooperation between HIF-1α and c-Jun in mediating primary and acquired resistance to gefitinib in NSCLC cells with activating mutation of EGFR.

Meng S, Wang G, Lu Y, Fan Z. Meng S, et al. Lung Cancer. 2018 Jul;121:82-90. doi: 10.1016/j.lungcan.2018.04.024. Epub 2018 May 1. Lung Cancer. 2018. PMID: 29858032 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

87 results

Results by year